AstraZeneca Stock: Undervalued and Worth Considering Despite Recent Pause and Price Slide

AstraZeneca's stock price has dropped 5.3% in the past week and 2.1% over the last month, but its long-term performance remains strong, with a 20% gain in the last three years and 48.3% gain over five years. The company's recent decision to pause a $270 million investment in Britain has added uncertainty, but the stock is undervalued by half of standard measures, making it a potential buying opportunity.

AstraZeneca's stock price has seen a recent downturn, with a 5.3% drop in the past week and a 2.1% decrease over the last month. However, the company's long-term performance remains robust, boasting a 20% gain over the last three years and a 48.3% increase over five years. Despite the recent decline, the stock is undervalued by half of standard measures, presenting a potential buying opportunity for investors.

The company's recent decision to pause a $270 million investment in Britain has introduced uncertainty into the market. AstraZeneca's stock price has been negatively impacted by this pause, which has raised questions about the company's future growth prospects. However, analysts remain optimistic about the company's long-term potential.

Analysts at Zacks Research have lifted their Q2 2026 EPS estimates for AstraZeneca, now anticipating earnings of $1.23 per share for the quarter, up from their prior estimate of $1.22 Q2 EPS Estimates for AstraZeneca Increased by Zacks Research^[1]. The consensus estimate for AstraZeneca's current full-year earnings is $4.51 per share, with estimates for FY2026 earnings at $5.03 EPS, Q1 2027 earnings at $1.28 EPS, Q2 2027 earnings at $1.39 EPS, and FY2027 earnings at $5.70 EPS Q2 EPS Estimates for AstraZeneca Increased by Zacks Research^[1].

Berenberg Bank has set a price target of $97.00 for AstraZeneca, with analysts assigning a consensus rating of "Moderate Buy" and an average price target of $86.00 Q2 EPS Estimates for AstraZeneca Increased by Zacks Research^[1]. The company reported a revenue increase of 16.1% year-over-year for Q2, with earnings per share hitting the consensus estimate of $1.09 Q2 EPS Estimates for AstraZeneca Increased by Zacks Research^[1].

Despite the recent setbacks, AstraZeneca's strong fundamentals and positive analyst ratings suggest that the company remains a solid investment opportunity. The company's focus on the discovery, development, manufacture, and commercialization of prescription medicines, along with its diverse portfolio of marketed products, positions it well for long-term growth.